Stocks of Oncorus Inc. (NASDAQ:ONCR) traded higher last session on Wall Street, down -11.00% to $0.10.
ONCR stock price is now -65.83% away from the 50-day moving average and -81.13% away from the 200-day moving average. The market capitalization of the company currently stands at $4.20M.
With the price target of $35, Maxim Group recently initiated with Buy rating for Oncorus Inc. (NASDAQ: ONCR).
In other news, Flynn James E, Possible Member of 10% Group sold 138,872 shares of the company’s stock on Dec 30. The stock was sold for $37,495 at an average price of $0.27. Upon completion of the transaction, the Possible Member of 10% Group now directly owns 284,697 shares in the company, valued at $28469.7. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 29, Possible Member of 10% Group Flynn James E sold 141,753 shares of the business’s stock. A total of $36,856 was realized by selling the stock at an average price of $0.26. This leaves the insider owning 299,917 shares of the company worth $29991.7. Insiders disposed of 551,663 shares of company stock worth roughly $55166.3 over the past 1 year. A total of 12.69% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ONCR stock. A new stake in Oncorus Inc. shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $2,000. UBS GROUP AG invested $1,000 in shares of ONCR during the first quarter. In total, there are 54 active investors with 65.20% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $0.1145 for Oncorus Inc. (NASDAQ: ONCR). During the past 12 months, Oncorus Inc. has had a low of $0.09 and a high of $1.90. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 1.50, and a quick ratio of 1.50. The fifty day moving average price for ONCR is $0.2936 and a two-hundred day moving average price translates $0.5330 for the stock.
The latest earnings results from Oncorus Inc. (NASDAQ: ONCR) was released for Mar, 2023.
Oncorus Inc.(ONCR) Company Profile
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.